Abstract O31 – Figure 1. Post‐vaccination SARS‐CoV‐2 IgG spike‐antibody titers, T‐cell responses and neutralisation against wild‐type and Delta variants in participants of the AGEhIV COVID‐19 substudy. P‐values, comparing people with HIV (PWHIV) and HIV‐negative controls, were calculated using Wilcoxon rank‐sum test. (A) Post‐vaccination SARS‐CoV‐2 IgG spike‐antibody titers in participants without (left panel) and with (right panel) prior SARS‐CoV‐2 infection, by HIV‐status and vaccine type. Resulting values are expressed as the median fluorescence intensity (MFI) of at least 50 beads per antigen. The dotted line represents the antibody non‐response cut‐off value (IgG S‐antibody titer <17.8 MFI). (B) Post‐vaccination SARS‐CoV‐2 T‐cell responses in participants without (left panel) and with (right panel) prior SARS‐CoV‐2 infection, by HIV‐status and vaccine type. Resulting values are expressed as the IFNγ release (in pg/mL, lower detection limit 0.09 pg/mL). (C) Post‐vaccination virus‐neutralisation against SARS‐CoV‐2 wild‐type and Delta variants in 40 PWHIV and 40 controls (1:1 matched on age, sex and vaccine type). Resulting values are expressed as the serum dilution at which 50% of the infectivity was inhibited (ID50).